We are a global, clinical stage biopharmaceutical company developing innovative therapeutics in the fields of immuno-oncology and inflammatory diseases.

Our discovery and development programs are driven by unmet medical and patient needs and strong science supported by our two patented transgenic mouse platforms for generating fully human monoclonal antibodies. We focus on developing an innovative pipeline of Next-Gen therapeutics through our internal R&D programs, collaborations with co-discovery and co-development partners and select acquisitions.

With operations in Cambridge, Massachusetts; Rotterdam, The Netherlands; and Shanghai/Suzhou, China, we also license our core platform technology to other companies and academic institutions globally.
友情链接:ag视讯百家乐  澳门网投资讯  永利国际娱乐  188bet金宝搏  玛雅娱乐app  k8电游  广东会最新地址  帝皇娱乐